These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8255435)

  • 1. Bioequivalency revisited: epitol versus tegretol.
    Oles KS; Gal P
    Neurology; 1993 Dec; 43(12):2435-6. PubMed ID: 8255435
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic bioequivalency study of brand name versus generic carbamazepine.
    Oles KS; Penry JK; Smith LD; Anderson RL; Dean JC; Riela AR
    Neurology; 1992 Jun; 42(6):1147-53. PubMed ID: 1603340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic substitution of antiepileptic medications in patients with epilepsy: is this a potential problem?
    Gauthier-Lewis M; Riley TT
    Am J Health Syst Pharm; 2009 Nov; 66(21):1903-4. PubMed ID: 19850781
    [No Abstract]   [Full Text] [Related]  

  • 4. Carbamazepine toxicity resulting from generic substitution.
    Gilman JT; Alvarez LA; Duchowny M
    Neurology; 1993 Dec; 43(12):2696-7. PubMed ID: 8255480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.
    Hartley R; Aleksandrowicz J; Bowmer CJ; Cawood A; Forsythe WI
    J Pharm Pharmacol; 1991 Feb; 43(2):117-9. PubMed ID: 1672895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is generic prescribing acceptable in epilepsy?
    Besag FM
    Drug Saf; 2000 Sep; 23(3):173-82. PubMed ID: 11005701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of gullibility.
    Roach ES
    Arch Neurol; 2009 Nov; 66(11):1418-20. PubMed ID: 19901178
    [No Abstract]   [Full Text] [Related]  

  • 8. Are generic drugs really inferior medicines?
    Moore N; Berdaï D; Bégaud B
    Clin Pharmacol Ther; 2010 Sep; 88(3):302-4. PubMed ID: 20725079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirements for generic anti-epileptic medicines: a regulatory perspective.
    Maliepaard M; Hekster YA; Kappelle A; van Puijenbroek EP; Elferink AJ; Welink J; Gispen-de Wied CC; Lekkerkerker FJ
    J Neurol; 2009 Dec; 256(12):1966-71. PubMed ID: 19603244
    [No Abstract]   [Full Text] [Related]  

  • 10. Generic prescribing in epilepsy.
    Drug Ther Bull; 2009 Dec; 47(12):141-4. PubMed ID: 20009042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management.
    Di Bonaventura C; Fattouch J; Fabbrini G; Manfredi M; Prencipe M; Giallonardo TA
    Epileptic Disord; 2007 Dec; 9(4):465-6. PubMed ID: 18055310
    [No Abstract]   [Full Text] [Related]  

  • 12. The value of specifying brand-name antiepileptic drugs.
    Ng YT
    Arch Neurol; 2009 Nov; 66(11):1415-6. PubMed ID: 19901176
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients.
    Silpakit O; Amornpichetkoon M; Kaojarern S
    Ann Pharmacother; 1997 May; 31(5):548-52. PubMed ID: 9161646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When do differences in dissolution profiles predict clinical problems?
    Ngo SN
    J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
    [No Abstract]   [Full Text] [Related]  

  • 15. [Do we need to be afraid of biosimilars?].
    Bergmann JF
    Rev Med Interne; 2012 Mar; 33(3):119-21. PubMed ID: 22100198
    [No Abstract]   [Full Text] [Related]  

  • 16. [Brand-name drugs and generics in the treatment of epilepsy: recommendations of the Russian Antiepileptic League].
    Avakian GN; Belousova ED; Burd SG; Vlasov PN; Gekht AB; Guzeva VI; Zavadenko NN; Zenkov LR; Karlov VA; Petrukhin AS;
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(5 Pt 2):23-5. PubMed ID: 23120785
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    Boylan LS
    Neurology; 2009 May; 72(21):1876; author reply 1876-7. PubMed ID: 19470974
    [No Abstract]   [Full Text] [Related]  

  • 18. What's the problem with generic antiepileptic drugs?: a call to action.
    Berg MJ
    Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
    [No Abstract]   [Full Text] [Related]  

  • 19. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy.
    Liow K; Barkley GL; Pollard JR; Harden CL; Bazil CW;
    Neurology; 2007 Apr; 68(16):1249-50. PubMed ID: 17438213
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review.
    Talati R; Scholle JM; Phung OP; Baker EL; Baker WL; Ashaye A; Kluger J; Coleman CI; White CM
    Pharmacotherapy; 2012 Apr; 32(4):314-22. PubMed ID: 22461121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.